JP2017514479A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514479A5 JP2017514479A5 JP2016564990A JP2016564990A JP2017514479A5 JP 2017514479 A5 JP2017514479 A5 JP 2017514479A5 JP 2016564990 A JP2016564990 A JP 2016564990A JP 2016564990 A JP2016564990 A JP 2016564990A JP 2017514479 A5 JP2017514479 A5 JP 2017514479A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- protected
- polynucleotide
- thiophosphoramidate
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 28
- 239000002777 nucleoside Substances 0.000 claims description 22
- -1 oxo phosphoramidate Chemical compound 0.000 claims description 21
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims description 18
- 239000000539 dimer Substances 0.000 claims description 17
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 239000000178 monomer Substances 0.000 claims description 11
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 55
- 108091033319 polynucleotide Proteins 0.000 claims 24
- 239000002157 polynucleotide Substances 0.000 claims 24
- 102000040430 polynucleotide Human genes 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 17
- 230000000694 effects Effects 0.000 claims 10
- 239000004615 ingredient Substances 0.000 claims 10
- 108010017842 Telomerase Proteins 0.000 claims 8
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 8
- 230000000295 complement effect Effects 0.000 claims 8
- 239000000306 component Substances 0.000 claims 8
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 8
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 8
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 8
- 125000003277 amino group Chemical group 0.000 claims 7
- 125000003835 nucleoside group Chemical group 0.000 claims 7
- 230000001590 oxidative effect Effects 0.000 claims 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 6
- 229910052799 carbon Inorganic materials 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 239000008186 active pharmaceutical agent Substances 0.000 claims 5
- 150000002431 hydrogen Chemical class 0.000 claims 5
- 229930024421 Adenine Natural products 0.000 claims 4
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims 4
- 229960000643 adenine Drugs 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 229940104302 cytosine Drugs 0.000 claims 4
- 125000006245 phosphate protecting group Chemical group 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 229940113082 thymine Drugs 0.000 claims 4
- 229940035893 uracil Drugs 0.000 claims 4
- 238000010511 deprotection reaction Methods 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 239000012011 nucleophilic catalyst Substances 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229910052796 boron Inorganic materials 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 150000008300 phosphoramidites Chemical class 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 238000005987 sulfurization reaction Methods 0.000 claims 2
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000005426 pharmaceutical component Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- SXADIBFZNXBEGI-UHFFFAOYSA-N phosphoramidous acid Chemical group NP(O)O SXADIBFZNXBEGI-UHFFFAOYSA-N 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 238000001308 synthesis method Methods 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461987396P | 2014-05-01 | 2014-05-01 | |
| US61/987,396 | 2014-05-01 | ||
| US201562151909P | 2015-04-23 | 2015-04-23 | |
| US62/151,909 | 2015-04-23 | ||
| PCT/US2015/028327 WO2015168310A1 (en) | 2014-05-01 | 2015-04-29 | Oligonucleotide compositions and methods of making the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088277A Division JP2018131453A (ja) | 2014-05-01 | 2018-05-01 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2019234301A Division JP2020050670A (ja) | 2014-05-01 | 2019-12-25 | オリゴヌクレオチド組成物及びその作製方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514479A JP2017514479A (ja) | 2017-06-08 |
| JP2017514479A5 true JP2017514479A5 (enExample) | 2018-07-12 |
| JP7040892B2 JP7040892B2 (ja) | 2022-03-23 |
Family
ID=54359301
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016564990A Active JP7040892B2 (ja) | 2014-05-01 | 2015-04-29 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2018088277A Pending JP2018131453A (ja) | 2014-05-01 | 2018-05-01 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2019234301A Withdrawn JP2020050670A (ja) | 2014-05-01 | 2019-12-25 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2021144677A Active JP7736489B2 (ja) | 2014-05-01 | 2021-09-06 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2022005584A Active JP7308309B2 (ja) | 2014-05-01 | 2022-01-18 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2023060170A Withdrawn JP2023073510A (ja) | 2014-05-01 | 2023-04-03 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2025188613A Pending JP2026016798A (ja) | 2014-05-01 | 2025-11-07 | オリゴヌクレオチド組成物及びその作製方法 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018088277A Pending JP2018131453A (ja) | 2014-05-01 | 2018-05-01 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2019234301A Withdrawn JP2020050670A (ja) | 2014-05-01 | 2019-12-25 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2021144677A Active JP7736489B2 (ja) | 2014-05-01 | 2021-09-06 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2022005584A Active JP7308309B2 (ja) | 2014-05-01 | 2022-01-18 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2023060170A Withdrawn JP2023073510A (ja) | 2014-05-01 | 2023-04-03 | オリゴヌクレオチド組成物及びその作製方法 |
| JP2025188613A Pending JP2026016798A (ja) | 2014-05-01 | 2025-11-07 | オリゴヌクレオチド組成物及びその作製方法 |
Country Status (33)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS61840B1 (sr) | 2004-07-02 | 2021-06-30 | Geron Corp | Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera |
| JOP20200257A1 (ar) * | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
| JP2018513127A (ja) | 2015-04-23 | 2018-05-24 | ジェロン・コーポレーションＧｅｒｏｎ Ｃｏｒｐｏｒａｔｉｏｎ | 多価カチオン塩組成物を用いたポリヌクレオチド調製方法 |
| ES2901099T3 (es) * | 2017-07-10 | 2022-03-21 | Geron Corp | Proceso mejorado para la preparación de imetelstat |
| KR102982955B1 (ko) | 2019-10-28 | 2026-06-29 | 제론 코포레이션 | 3-팔미토일-아미도-1,2-프로판다이올 및 3-팔미토일-아미도-2-하이드록시-1-다이메톡시트라이페닐메틸에터-프로판의 결정질 고체 및 이의 제조 및 사용 방법 |
| IL292328B2 (en) * | 2019-10-28 | 2025-10-01 | Geron Corp | Succinylate-converted 3-(amido fatty acid)-2-hydroxy-1-(protected hydroxy)-propane salts, amorphous solids and methods for their preparation |
| JP7657736B2 (ja) * | 2020-01-08 | 2025-04-07 | 日東電工株式会社 | セグメント型アミダイトを用いた核酸合成法 |
| WO2023069865A1 (en) | 2021-10-15 | 2023-04-27 | Codexis, Inc. | Engineered terminal deoxynucleotidyl transferase variants |
| KR20250008345A (ko) | 2023-07-07 | 2025-01-14 | 주식회사 엘지에너지솔루션 | 체결기구 및 체결기구를 포함하는 전지팩 |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4046720A (en) | 1974-01-17 | 1977-09-06 | California Institute Of Technology | Crosslinked, porous, polyacrylate beads |
| US4394448A (en) | 1978-02-24 | 1983-07-19 | Szoka Jr Francis C | Method of inserting DNA into living cells |
| US4413070A (en) | 1981-03-30 | 1983-11-01 | California Institute Of Technology | Polyacrolein microspheres |
| US4678814A (en) | 1981-03-30 | 1987-07-07 | California Institute Of Technology | Polyacrolein microspheres |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US6448392B1 (en) | 1985-03-06 | 2002-09-10 | Chimerix, Inc. | Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use |
| US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
| US4757141A (en) | 1985-08-26 | 1988-07-12 | Applied Biosystems, Incorporated | Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof |
| US4659774A (en) | 1985-11-01 | 1987-04-21 | American Hoechst Corporation | Support for solid-phase oligonucleotide synthesis |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| WO1990010448A2 (en) | 1989-03-07 | 1990-09-20 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US6395492B1 (en) | 1990-01-11 | 2002-05-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6153737A (en) | 1990-01-11 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Derivatized oligonucleotides having improved uptake and other properties |
| US6114513A (en) | 1990-01-11 | 2000-09-05 | Isis Pharmaceuticals, Inc. | Thiol-derivatized oligonucleotides |
| AU7759291A (en) | 1990-03-29 | 1991-10-21 | Gilead Sciences, Inc. | Oligonucleotide-transport agent disulfide conjugates |
| US5420330A (en) | 1990-09-07 | 1995-05-30 | Pharmacia P-L Biochemicals Inc. | Lipo-phosphoramidites |
| US5419966A (en) | 1991-06-10 | 1995-05-30 | Microprobe Corporation | Solid support for synthesis of 3'-tailed oligonucleotides |
| US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
| US5629154A (en) | 1993-11-12 | 1997-05-13 | Geron Corporation | Telomerase activity assays |
| US5489508A (en) | 1992-05-13 | 1996-02-06 | University Of Texas System Board Of Regents | Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| US5837453A (en) | 1992-05-13 | 1998-11-17 | Geron Corporation | Telomerase activity assays |
| US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
| IL107150A0 (en) | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
| US7067497B2 (en) | 1992-09-29 | 2006-06-27 | Isis Pharmaceuticals, Inc. | Modulation of telomere length by oligonucleotides having a G-core sequence |
| US6087491A (en) | 1993-01-08 | 2000-07-11 | Hybridon, Inc. | Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks |
| US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
| US6350853B1 (en) | 1993-04-26 | 2002-02-26 | Peter E. Nielsen | Conjugated peptide nucleic acids having enhanced cellular uptake |
| DE4331670A1 (de) | 1993-09-17 | 1995-03-23 | Hoechst Ag | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung |
| WO1995011253A1 (en) | 1993-10-18 | 1995-04-27 | The Walter And Eliza Hall Institute Of Medical Research | A method for enhancing neurone survival and agents useful for same |
| US5863726A (en) | 1993-11-12 | 1999-01-26 | Geron Corporation | Telomerase activity assays |
| US5726297A (en) | 1994-03-18 | 1998-03-10 | Lynx Therapeutics, Inc. | Oligodeoxyribonucleotide N3' P5' phosphoramidates |
| US5599922A (en) | 1994-03-18 | 1997-02-04 | Lynx Therapeutics, Inc. | Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties |
| HUT76094A (en) | 1994-03-18 | 1997-06-30 | Lynx Therapeutics | Oligonucleotide n3'-p5' phosphoramidates: synthesis and compounds; hybridization and nuclease resistance properties |
| GB9413035D0 (en) | 1994-06-29 | 1994-08-17 | Scras | Antisense oligonucleeotides |
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| JPH10505488A (ja) | 1994-07-07 | 1998-06-02 | ジェロン コーポレイション | 哺乳動物のテロメラーゼ |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| JPH10509447A (ja) | 1994-11-07 | 1998-09-14 | ハイブライドン インコーポレイテッド | ３ｈ−１，２−ベンゾジチオール−３−１，１−ジオキシドを用いた▲上３５▼ｓ−標識オリゴヌクレオチドの合成 |
| US5656638A (en) | 1995-04-18 | 1997-08-12 | Geron Corporation | Telomerase inhibitors |
| US5863936A (en) | 1995-04-18 | 1999-01-26 | Geron Corporation | Telomerase inhibitors |
| US5760062A (en) | 1995-04-18 | 1998-06-02 | Geron Corporation | Telomerase inhibitors |
| US5840490A (en) | 1995-06-07 | 1998-11-24 | Mcmaster University | Telomerase activity associated with hematological and colorectal malignancies |
| US5770613A (en) | 1995-09-29 | 1998-06-23 | Geron Corporation | Telomerase inhibitors |
| US5767278A (en) | 1995-10-06 | 1998-06-16 | Geron Corporation | Telomerase inhibitors |
| US5859233A (en) | 1996-02-21 | 1999-01-12 | Lynx Therapeutics, Inc. | Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| GB9606158D0 (en) | 1996-03-23 | 1996-05-29 | Ciba Geigy Ag | Chemical compounds |
| US6015710A (en) | 1996-04-09 | 2000-01-18 | The University Of Texas System | Modulation of mammalian telomerase by peptide nucleic acids |
| WO1997037691A1 (en) * | 1996-04-10 | 1997-10-16 | Lynx Therapeutics, Inc. | Telomerase inhibitors |
| US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
| US6444650B1 (en) | 1996-10-01 | 2002-09-03 | Geron Corporation | Antisense compositions for detecting and inhibiting telomerase reverse transcriptase |
| US6261836B1 (en) | 1996-10-01 | 2001-07-17 | Geron Corporation | Telomerase |
| US6001991A (en) | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
| EP0951568A1 (en) | 1996-12-20 | 1999-10-27 | Geron Corporation | Methods for detecting and inhibiting the rna component of telomerase |
| US5846723A (en) | 1996-12-20 | 1998-12-08 | Geron Corporation | Methods for detecting the RNA component of telomerase |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US5998604A (en) | 1997-09-15 | 1999-12-07 | The Perkin-Elmer Corporation | Polynucleotide purification method |
| JP3722630B2 (ja) | 1998-10-28 | 2005-11-30 | パイオニア株式会社 | 記録再生装置 |
| US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
| HK1049339B (en) | 1999-09-10 | 2008-06-27 | Geron Corporation | Oligonucleotide n3'-p5' thiophosphoramidates: their synthesis and use |
| GB9927674D0 (en) * | 1999-11-23 | 2000-01-19 | Aegis Eng Ltd | Protective material |
| US6331399B1 (en) | 2000-05-16 | 2001-12-18 | Isis Pharmaceuticals, Inc. | Antisense inhibition of tert expression |
| US7563618B2 (en) | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| AU2002245717A1 (en) | 2001-03-23 | 2002-10-08 | Geron Corporation | Oligonucleotide conjugates |
| US20120329858A1 (en) | 2010-08-04 | 2012-12-27 | Geron Corporation | Modified oligonucleotides for telomerase inhibition |
| DK3342425T3 (da) | 2003-09-09 | 2020-03-16 | Geron Corp | Modificerede oligonukleotider til inhibering af telomerase |
| RS61840B1 (sr) | 2004-07-02 | 2021-06-30 | Geron Corp | Sinteza zaštićenih 3'-amino 5'-fosforamidit nukleozidnih monomera |
| WO2006023880A2 (en) * | 2004-08-23 | 2006-03-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
| AU2005295351A1 (en) * | 2004-10-18 | 2006-04-27 | Codon Devices, Inc. | Methods for assembly of high fidelity synthetic polynucleotides |
| EP1876893B1 (en) | 2005-04-15 | 2012-04-11 | Geron Corporation | Cancer treatment by combined inhibition of proteasome and telomerase activities |
| WO2007127163A2 (en) * | 2006-04-24 | 2007-11-08 | Geron Corporation | Cns-tumor treatment method and composition |
| EP4600359A2 (en) | 2006-10-30 | 2025-08-13 | Geron Corporation | Combined telomerase inhibitor and gemcitabine for the treatment of cancer |
| WO2008094640A2 (en) * | 2007-01-30 | 2008-08-07 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| US9106103B2 (en) | 2011-09-23 | 2015-08-11 | Eaton Corporation | Unintteruptible power supply systems and methods employing on-demand energy storage |
| US9006630B2 (en) | 2012-01-13 | 2015-04-14 | Altasens, Inc. | Quality of optically black reference pixels in CMOS iSoCs |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| US20150342982A1 (en) | 2012-12-07 | 2015-12-03 | Geron Corporation | Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms |
| JOP20200257A1 (ar) | 2014-05-01 | 2017-06-16 | Geron Corp | تركيبات أوليجو نوكليوتيد وطرق لتحضيرها |
-
2014
- 2014-05-01 JO JOP/2020/0257A patent/JOP20200257A1/ar unknown
-
2015
- 2015-04-29 MY MYPI2016703971A patent/MY178617A/en unknown
- 2015-04-29 WO PCT/US2015/028327 patent/WO2015168310A1/en not_active Ceased
- 2015-04-29 ES ES15785822T patent/ES2963740T3/es active Active
- 2015-04-29 HR HRP20231505TT patent/HRP20231505T1/hr unknown
- 2015-04-29 TW TW108147051A patent/TWI712413B/zh active
- 2015-04-29 EP EP23193452.2A patent/EP4286519A3/en active Pending
- 2015-04-29 MY MYPI2020002421A patent/MY196927A/en unknown
- 2015-04-29 MA MA63525A patent/MA63525B1/fr unknown
- 2015-04-29 KR KR1020237018801A patent/KR20230088509A/ko not_active Ceased
- 2015-04-29 AP AP2016009489A patent/AP2016009489A0/en unknown
- 2015-04-29 SG SG11201608226YA patent/SG11201608226YA/en unknown
- 2015-04-29 UA UAA201610381A patent/UA126108C2/uk unknown
- 2015-04-29 PE PE2016002150A patent/PE20170147A1/es unknown
- 2015-04-29 KR KR1020167029996A patent/KR102316282B1/ko active Active
- 2015-04-29 EA EA201691786A patent/EA034882B9/ru unknown
- 2015-04-29 US US14/699,902 patent/US9796747B2/en active Active
- 2015-04-29 CN CN202010050944.5A patent/CN111228288B/zh active Active
- 2015-04-29 KR KR1020217033531A patent/KR102707216B1/ko active Active
- 2015-04-29 PL PL15785822.6T patent/PL3137479T3/pl unknown
- 2015-04-29 LT LTEPPCT/US2015/028327T patent/LT3137479T/lt unknown
- 2015-04-29 MX MX2016014178A patent/MX382233B/es unknown
- 2015-04-29 DK DK15785822.6T patent/DK3137479T5/da active
- 2015-04-29 SG SG10201911086XA patent/SG10201911086XA/en unknown
- 2015-04-29 HU HUE15785822A patent/HUE064289T2/hu unknown
- 2015-04-29 CN CN201580022353.4A patent/CN106459134B/zh active Active
- 2015-04-29 SI SI201531963T patent/SI3137479T1/sl unknown
- 2015-04-29 AU AU2015253158A patent/AU2015253158B2/en active Active
- 2015-04-29 JP JP2016564990A patent/JP7040892B2/ja active Active
- 2015-04-29 CN CN202311295220.7A patent/CN117357548A/zh active Pending
- 2015-04-29 RS RS20231110A patent/RS64860B1/sr unknown
- 2015-04-29 BR BR112016025196-2A patent/BR112016025196B1/pt active IP Right Grant
- 2015-04-29 JO JOP/2015/0089A patent/JO3767B1/ar active
- 2015-04-29 TW TW104113709A patent/TWI709406B/zh active
- 2015-04-29 EP EP15785822.6A patent/EP3137479B1/en active Active
- 2015-04-29 PT PT157858226T patent/PT3137479T/pt unknown
- 2015-04-29 FI FIEP15785822.6T patent/FI3137479T3/fi active
- 2015-04-29 KR KR1020247031813A patent/KR20240144488A/ko active Pending
- 2015-04-29 SM SM20230405T patent/SMT202300405T1/it unknown
-
2016
- 2016-09-23 ZA ZA2016/06624A patent/ZA201606624B/en unknown
- 2016-09-26 IL IL248044A patent/IL248044B/en active IP Right Grant
- 2016-10-19 PH PH12016502080A patent/PH12016502080A1/en unknown
- 2016-10-28 CL CL2016002749A patent/CL2016002749A1/es unknown
- 2016-10-28 MX MX2021004932A patent/MX2021004932A/es unknown
-
2017
- 2017-09-14 US US15/705,019 patent/US10392418B2/en active Active
- 2017-09-14 US US15/705,021 patent/US11299511B2/en active Active
-
2018
- 2018-05-01 JP JP2018088277A patent/JP2018131453A/ja active Pending
- 2018-05-04 CL CL2018001213A patent/CL2018001213A1/es unknown
- 2018-05-04 CL CL2018001212A patent/CL2018001212A1/es unknown
-
2019
- 2019-08-07 IL IL268570A patent/IL268570B/en unknown
- 2019-12-25 JP JP2019234301A patent/JP2020050670A/ja not_active Withdrawn
-
2020
- 2020-03-06 AU AU2020201707A patent/AU2020201707B2/en active Active
- 2020-09-22 ZA ZA2020/05857A patent/ZA202005857B/en unknown
-
2021
- 2021-09-06 JP JP2021144677A patent/JP7736489B2/ja active Active
-
2022
- 2022-01-18 JP JP2022005584A patent/JP7308309B2/ja active Active
- 2022-01-26 CL CL2022000202A patent/CL2022000202A1/es unknown
- 2022-03-16 US US17/696,300 patent/US11739114B2/en active Active
- 2022-05-16 AU AU2022203273A patent/AU2022203273A1/en not_active Abandoned
-
2023
- 2023-04-03 JP JP2023060170A patent/JP2023073510A/ja not_active Withdrawn
- 2023-06-07 US US18/330,935 patent/US20240150391A1/en not_active Abandoned
-
2024
- 2024-01-05 US US18/405,775 patent/US20250011359A1/en not_active Abandoned
-
2025
- 2025-11-07 JP JP2025188613A patent/JP2026016798A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2071483C (en) | Oligonucleotide analogs with novel linkages | |
| US9169256B2 (en) | Artificial nucleic acids | |
| JP2021182946A5 (enExample) | ||
| JP5981985B2 (ja) | キャプチャータグを用いた、三リン酸化オリゴヌクレオチドの精製 | |
| JP2017518966A (ja) | リン保護基ならびにそれらの調製方法および使用 | |
| KR20210130822A (ko) | 올리고뉴클레오타이드 조성물 및 이를 제조하는 방법 | |
| JP3675847B2 (ja) | ヌクレオチド又はオリゴヌクレオチドホスホロアミダイトの合成方法 | |
| US12264174B2 (en) | Process for preparing imetelstat | |
| JP7719788B2 (ja) | 核酸オリゴマーの製造方法 | |
| JP7452549B2 (ja) | ホスホロアミダイト活性化剤 | |
| US8680262B2 (en) | Purification of oligonucleotides | |
| KR20250046255A (ko) | 티오화 용액 | |
| US6441150B1 (en) | Compounds for the Synthesis of Nucleotide or oligonucleotide phosphoramidites | |
| JP2008524163A (ja) | ４級ヘテロ環活性剤を用いたホスフィチル化した化合物の合成 |